Minerva Neurosciences, Inc - Common Stock (NERV)
2.3100
-0.0700 (-2.94%)
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of neuropsychiatric diseases
The company is dedicated to addressing unmet medical needs in areas such as schizophrenia and insomnia, utilizing a deep understanding of neuroscience to create potential drug candidates. With a robust pipeline of investigational therapies, Minerva works to advance novel treatments that aim to improve the quality of life for patients suffering from these complex disorders. Through rigorous research and clinical trials, Minerva seeks to enhance therapeutic options and outcomes in the field of mental health.